{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:12:10Z","timestamp":1793502730072,"version":"4.5.0"},"reference-count":33,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Daiichi Sankyo Co., Ltd","award":["T-DXd"],"award-info":[{"award-number":["T-DXd"]}]},{"name":"Daiichi Sankyo Co., Ltd","award":["DS-8201"],"award-info":[{"award-number":["DS-8201"]}]},{"award":["T-DXd"],"award-info":[{"award-number":["T-DXd"]}],"id":[{"id":"https:\/\/ror.org\/027y26122","id-type":"ROR","asserted-by":"publisher"}]},{"award":["DS-8201"],"award-info":[{"award-number":["DS-8201"]}],"id":[{"id":"https:\/\/ror.org\/027y26122","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Limited data exist on the prevalence of human epidermal growth factor receptor 2 (ERBB2\/HER2) amplification in patients with all types of solid tumors. This retrospective, observational study (UMIN ID: UMIN000057382) analyzed the prevalence of HER2 amplification across all solid tumors using comprehensive genomic profiling (CGP) data from the Center for Cancer Genomics and Advanced Therapeutics database in Japan. We analyzed 89,374 eligible patients with solid tumors: HER2 amplification was detected in 5119 patients (5.7%). The highest rates of HER2 amplification were observed in patients with tumors of the esophagus\/stomach (12.9%), followed by tumors of the bladder\/urinary tract (10.6%), breast (9.5%), biliary tract (8.4%), and uterus (8.4%). Among the five assay platforms, FoundationOne CDx accounted for 69.7% of all CGP tests and had an HER2 amplification detection rate of 7.4%, compared to the other four platforms (range: 1.9\u201315.4% of all CGP tests [detection rates: 1.5\u20132.3%]). Substantial differences were observed in the mutation frequencies of multiple genes between HER2 amplified and HER2 non-amplified tumors. The results highlight that HER2 amplification extends beyond conventional tumor types and enables the identification, via CGP testing, of non-traditional tumor subsets (cancers other than breast and gastric cancer), including rare cancers, that could be candidates for HER2-targeting therapy such as trastuzumab deruxtecan in Japan.<\/jats:p>","DOI":"10.3390\/curroncol33040195","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T08:09:18Z","timestamp":1774944558000},"page":"195","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Tumor-Agnostic Landscape with HER2 Amplification in Japan: Real-World Prevalence and Implications for Targeting HER2"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3128-1477","authenticated-orcid":false,"given":"Yutaka","family":"Hatanaka","sequence":"first","affiliation":[{"name":"Center for Development of Advanced Diagnostics, Hokkaido University Hospital, Sapporo, Hokkaido 060-8648, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4813-9510","authenticated-orcid":false,"given":"Jun","family":"Sasano","sequence":"additional","affiliation":[{"name":"Oncology Medical Science Department, Daiichi Sankyo Co., Ltd., Chuo-ku, Tokyo 103-8426, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Takizawa","sequence":"additional","affiliation":[{"name":"Data Intelligence Department, Daiichi Sankyo Co., Ltd., Shinagawa-ku, Tokyo 140-0005, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"852748","DOI":"10.1155\/2014\/852748","article-title":"Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Mol. Biol. Int."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update","volume":"41","author":"Wolff","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1056\/NEJMp058197","article-title":"The Distinctive Nature of HER2-Positive Breast Cancers","volume":"353","author":"Burstein","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-Targeted Therapies\u2014A Role Beyond Breast Cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10555-015-9552-6","article-title":"HER2 Expression Status in Diverse Cancers: Review of Results From 37,992 Patients","volume":"34","author":"Yan","year":"2015","journal-title":"Cancer Metastasis Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1200\/JCO.23.02626","article-title":"Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial","volume":"42","author":"Yagisawa","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1158\/2159-8290.CD-22-0417","article-title":"C-CAT: The National Datacenter for Cancer Genomic Medicine in Japan","volume":"12","author":"Kohno","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1158\/2159-8290.CD-23-0902","article-title":"Pan-Cancer Comparative and Integrative Analyses of Driver Alterations Using Japanese and International Genomic Databases","volume":"14","author":"Horie","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1158\/1078-0432.CCR-18-2275","article-title":"Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer","volume":"25","author":"Johnson","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR Project GENIE: Powering Precision Medicine Through an International Consortium","volume":"7","author":"Arnedos","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_11","unstructured":"(2025, September 29). Cancer Genomic Medicine and Cancer Gene Panel Testing. C-CAT Registration Status. Available online: https:\/\/for-patients.c-cat.ncc.go.jp\/registration_status\/."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e7351","DOI":"10.1002\/cam4.7351","article-title":"Prevalence of Neurotrophic Tropomyosin Receptor Kinase (NTRK) Fusion Gene Positivity in Patients With Solid Tumors in Japan","volume":"13","author":"Nakata","year":"2024","journal-title":"Cancer Med."},{"key":"ref_13","unstructured":"National Cancer Center Japan (2025, August 30). List of Information Providers and Issues, Available online: https:\/\/www.ncc.go.jp\/jp\/c_cat\/use\/release\/index.html."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1200\/CCI.20.00108","article-title":"OncoTree: A Cancer Classification System for Precision Oncology","volume":"5","author":"Kundra","year":"2021","journal-title":"JCO Clin. Cancer Inform."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies","volume":"335","author":"Altman","year":"2007","journal-title":"BMJ"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"ref_17","first-page":"21","article-title":"HER2 Amplification by Next-Generation Sequencing in Lung Carcinoma: A Comparison of NGS Amplified and Non-Amplified Cases by Immunohistochemistry and In Situ Hybridization","volume":"39","author":"Karasoy","year":"2022","journal-title":"Balkan Med. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00345","article-title":"Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients with Advanced or Metastatic Solid Tumors Beyond Conventional Indications","volume":"3","author":"Dumbrava","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/ajcp\/aqz031","article-title":"Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal Carcinoma","volume":"152","author":"Cenaj","year":"2019","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1158\/2767-9764.CRC-24-0620","article-title":"Diverse ERBB2\/ERBB3 Activating Alterations and Coalterations Have Implications for HER2\/3-Targeted Therapies Across Solid Tumors","volume":"5","author":"Liu","year":"2025","journal-title":"Cancer Res. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Bonomi, M., Spada, D., Baiocchi, G.L., Celotti, A., Brighenti, M., and Grizzi, G. (2024). Targeting HER2 in Gastroesophageal Adenocarcinoma: Molecular Features and Updates in Clinical Practice. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25073876"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","article-title":"Pertuzumab Plus Trastuzumab for HER2-Amplified Metastatic Colorectal Cancer (MyPathway): An Updated Report From a Multicentre, Open-Label, Phase 2a, Multiple Basket Study","volume":"20","author":"Hurwitz","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S239","DOI":"10.1016\/j.annonc.2023.09.2872","article-title":"148P DESTINY-PanTumor02 study of Trastuzumab Deruxtecan (T-DXd) in Patients (pts) With HER2-Expressing Solid Tumors: Exploratory Biomarker Analyses of HER2 Expression and Gene Amplification in Tissue and Plasma","volume":"34","author":"Makker","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_24","unstructured":"(2025, October 27). FoundationOne\u00aeCDx. Technical Information, Available online: https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf17\/P170019S006C.pdf."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/modpathol.2015.57","article-title":"Sequencing of 279 Cancer Genes in Ampullary Carcinoma Reveals Trends Relating to Histologic Subtypes and Frequent Amplification and Overexpression of ERBB2 (HER2)","volume":"28","author":"Hechtman","year":"2015","journal-title":"Mod. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1200\/JCO.22.02636","article-title":"MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors","volume":"42","author":"Sweeney","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s00292-020-00878-6","article-title":"ISH-Based HER2 Diagnostics","volume":"42","author":"Nagelmeier","year":"2021","journal-title":"Pathologe"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1111\/cas.70077","article-title":"First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors: 1-Year Follow-Up of the FIRST-Dx Study","volume":"116","author":"Matsubara","year":"2025","journal-title":"Cancer Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1093\/jjco\/hyab159","article-title":"Study Protocol for NCCH1908 (UPFRONT-Trial): A Prospective Clinical Trial to Evaluate the Feasibility and Utility of Comprehensive Genomic Profiling Prior to the Initial Systemic Treatment in Advanced Solid Tumour Patients","volume":"51","author":"Mizuno","year":"2021","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_30","unstructured":"(2025, September 13). Supplement to the 2nd Edition of the HER2 Pathological Diagnosis Guidance for Solid Tumors [Internet]. Japanese Society of Pathology. Available online: https:\/\/www.pathology.or.jp\/news\/20231218_guidance20221228.pdf."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1111\/cas.15517","article-title":"Chronological Improvement in Precision Oncology Implementation in Japan","volume":"113","author":"Sunami","year":"2022","journal-title":"Cancer Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1111\/cas.15586","article-title":"Clinical Utility of Comprehensive Genomic Profiling Tests for Advanced or Metastatic Solid Tumor in Clinical Practice","volume":"113","author":"Ida","year":"2022","journal-title":"Cancer Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1111\/cas.15993","article-title":"Prognostic Impact of Cancer Genomic Profile Testing for Advanced or Metastatic Solid Tumors in Clinical Practice","volume":"114","author":"Fukada","year":"2023","journal-title":"Cancer Sci."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/4\/195\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T16:25:40Z","timestamp":1775060740000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/4\/195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["curroncol33040195"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33040195","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]}}}